A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma
Introduction
Lung cancer is the leading cause of cancer-related death with over one million deaths annually worldwide and over 160,000 deaths in the US in 2004 [1]. Non-small cell lung carcinoma (NSCLC) accounts for 80% of lung cancer diagnoses [2]. Most NSCLC patients are diagnosed with advanced stage disease not amenable to surgical cure [3]. Although some stage III patients can be cured with combined modality therapy, most advanced stage patients receive chemotherapy alone resulting in clinical response or disease stabilization in many cases, but with few long-term survivors [4], [5], [6]. Front line treatment with platinum doublet chemotherapy now produces median survivals of 8–11 months and provides clinically meaningful overall survival benefits, with 1 year survivals for stage IV NSCLC patients of 30–50% compared to 5–10% for patients receiving supportive care alone.
Taxanes are among the most active NSCLC chemotherapies acting on cells in the G2/M phase of the cell cycle by stabilizing microtubules, thus, disrupting normal mitosis and leading to activation of apoptotic pathways in sensitive cells. Both paclitaxel and docetaxel are approved in combination with cisplatin for first line therapy of NSCLC. Docetaxel is also approved as a single agent for patients who have failed first line chemotherapy and is associated with quality of life gains and survival benefits similar to those seen with first line therapy. Patients treated with second line docetaxel have about a 30% chance of living 1 year [7], [8]. In the face of these modest gains, new approaches to systemic therapy of advanced NSCLC are needed.
Anthracyclines have low single agent activity against NSCLC, but doxorubicin was a component of CAP (cyclophosphamide, doxorubicin, and cisplatin), one of the first chemotherapy regimens to show a survival benefit in this disease [9]. Anthracyclines have been largely supplanted in recent combination chemotherapy regimens in favor of newer agents. However, if effective targeting can increase the specificity of drug delivery and if rational combinations successfully exploit synergistic cell cycle dependent interactions, they may hold greater promise than previously appreciated.
SGN-15 (cBR96-doxorubicin conjugate) is a novel antibody–drug conjugate that targets doxorubicin to tissues expressing the Ley antigen. This carbohydrate antigen is abundantly expressed (>200,000 molecules/cell) by carcinoma cells [10]. Tissue binding studies show that cBR96 targets a wide variety of human carcinomas including lung, breast, colon, prostate, and ovary [10]. cBR96 also targets normal cells expressing Ley, including differentiated epithelial cells of the GI tract and acinar cells of the pancreas. SGN-15 consists of doxorubicin conjugated to cBR96 at a molar ratio of 8:1 with 6 mg doxorubicin per 200 mg SGN-15. Phase I studies of SGN-15 showed evidence of activity in patients with Ley expressing tumors [11]. Of 58 evaluable patients, 21 (36%) had stable disease after 6 weeks and there were two partial responses.
SGN-15 and docetaxel are synergistic in preclinical studies. Following exposure to doxorubicin, cells arrest in G2 [12] and are then sensitized to G2/M acting drugs such as taxanes. In vitro studies [13] and animal models [14] confirm that the combination of SGN-15 plus a taxane is more effective than either drug alone in several tumor types. Phases I and II studies in subjects with epithelial malignancies, including metastatic breast and colorectal carcinomas, confirm that the combination of SGN-15 and docetaxel is safe and clinically active [15], [16], [17], [18] (unpublished data, Seattle Genetics, Inc.). In 29 evaluable patients with breast cancer, the disease control rate (i.e. stable disease or better) was 41% (seven stable disease [SD], two minimal response [MR], three partial response [PR]). Among 20 evaluable patients with colorectal carcinoma, the disease control rate was 20% (three SD, one MR). The toxicity profile was acceptable with gastrointestinal toxicities occurring most frequently. Other toxicities were mild and infrequent.
We now report the results of a randomized Phase II, multicenter study designed to determine the safety and efficacy of SGN-15 and docetaxel in patients with NSCLC.
Section snippets
Patients
Patients with recurrent or progressive advanced non-small cell lung cancer not amenable to therapy with curative intent were eligible for this trial if they had failed at least one but not more than two prior chemotherapy regimens at least one of which must have contained a platinum. Patients must have been at least 4 weeks past prior treatment with recovery from significant toxicities. Measurable or evaluable disease, ECOG performance status (PS) ≤ 2, age at least 18 years, and life expectancy
Results
Sixty-two subjects were enrolled at 11 sites between August 2001 and April 2003. Three patients did not receive study treatment: one patient in Arm A had a decline in PS prior to treatment and was removed from the study and two patients in Arm B withdrew consent prior to treatment. Fifty-nine patients, 40 in Arm A and 19 in Arm B, received at least one dose of study medication and were evaluated for survival and toxicity. The median number of weeks on study treatment was 8.2 in Arm A and 8.1 in
Discussion and conclusion
This randomized Phase II study shows that the combination of SGN-15 and docetaxel is active in NSCLC patients who have failed up to two chemotherapy regimens including at least one platinum-containing regimen. The study treatment was well tolerated without a clinically meaningful difference in toxicity of the combination arm compared to weekly docetaxel alone. Patients on the combination arm had a longer median survival (31.4 weeks versus 25.3 weeks) and a better chance of living 18 months (18%
Conflict of interest
All authors, with the exception of those employed by Seattle Genetics, have indicated no potential conflicts of interest. The employees of or contractors to Seattle Genetics include Laurie Grove, Michael Thorn, Dennis Miller, and Jonathan Drachman.
Acknowledgements
Sincere thanks are extended to Michael MacDonald, MD, Amy Sing, MD, Andrew Sandier, MD, J. Michael White, PhD, Jennie Lorenz, CCRA, Katie Herz, CRA, Brenda Fisher, RN, Esther Bit-Ivan, Livia Szeto, RN, Cara O’Keefe, Joanne Jelliffe, Christine Baker, RN, Heather Houston, RN, Cheryl Elzinga, Inger Thompson, Carol Ford, RN, Diane Perry, RN, and all of the clinical trial site personnel for their assistance in conducting this trial. We are grateful to Stephanie Boyer for her invaluable assistance in
References (25)
- et al.
Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer
Semin Oncol
(2005) - et al.
Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument
Lung Cancer
(1995) Preclinical pharmacology of docetaxel
Eur J Cancer
(1995)Cancer facts and figures
(2004)- et al.
Cancer statistics 1999
CA Cancer J Clin
(1999) Continuing controversies in staging NSCLC: an analysis of the revised 1997 staging system
Oncology (Williston Park)
(1998)- et al.
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504
J Clin Oncol
(2003) - et al.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
N Engl J Med
(2002) - et al.
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group
J Clin Oncol
(2000) - et al.
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
J Clin Oncol
(2000)
Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer
Cancer Treat Rep
Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens
Cancer Res
Cited by (33)
Glycan Arrays: Construction, Detection, and Analysis
2021, Comprehensive Glycoscience: Second EditionImmunoconjugates as immune canoes to kill breast cancer cells
2020, Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical PerspectivesAntibody drug conjugates in thoracic malignancies
2018, Lung CancerCitation Excerpt :The ORR was 6% with SGN-15 + docetaxel and 21% with docetaxel. Survival was numerically greater in the experimental arm (mPFS 10.9 weeks and mOS 31.4 weeks) when compared to docetaxel alone (mPFS 7 weeks and mOS 25.3 weeks) [43]. PF-7020 is an ADC, with an auristatin cytotoxic attached to the antibody via a cleavable linker, which targets protein tyrosine kinase 7 (PTK7).
Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies
2018, Clinical Lymphoma, Myeloma and LeukemiaCitation Excerpt :ADCs developed in the 1970s through the 1990s generally provided disappointing clinical results.12 The payloads were commonly used chemotherapeutic drugs such as 5-fluorouracil and doxorubicin, which most likely lacked sufficient potency.13 Other problems included the selection of appropriate antigens, the use of murine antibodies, and inadequate linker stability.
Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies
2015, Molecular ImmunologyCitation Excerpt :Patients receiving SGN-15 and docetaxel showed modest increases in survival (29% and 18% at 12 and 18 months) compared to those treated with docetaxel alone (18% and 8% at 12 and 18 months). Only mild-treatment related side effects were noted in both study arms (Ross et al., 2006). Early Phase I clinical trials with hu3S193 in patients with advanced colorectal, lung and ovarian cancer have shown promising safety and in vivo tumor targeting properties with minimal binding to normal tissues (Krug et al., 2007; Scott et al., 2007).
A new system for targeted delivery of doxorubicin into tumor cells
2013, Journal of Controlled ReleaseCitation Excerpt :The most effective delivery systems are those comprising vector molecules that can selectively bind to specific receptors on the surface of tumor cells and can be internalized by cells, with the internalization of drug. Serum albumin [1], transferrin [2], folic acid [3], and chimeric or humanized monoclonal antibodies to tumor cell surface antigens [4,5] are most often used as vectors. In our opinion, using the oncofetal alpha-fetoprotein (AFP) receptor as a target is a promising approach.
- 1
Present address: ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102-3702, United States.
- 2
Present address: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building I, Room 344, 1650 Orleans Street, Baltimore, MD 21231, United States.